Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Raltegravir monotherapy and in combination with Etravirine in patient with virological failure and treatment-experienced but had not previously received RAL or another integrase strand-transfer inhibitor.

Next Previous
Trial Profile

Efficacy of Raltegravir monotherapy and in combination with Etravirine in patient with virological failure and treatment-experienced but had not previously received RAL or another integrase strand-transfer inhibitor.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etravirine (Primary) ; Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use

Most Recent Events

  • 21 Sep 2017 New trial record
  • 01 Aug 2017 Results assessing efficacy of raltegravir as monotherapy and in combination with etravirine in patient with virological failure and treatment-experienced but had not previously received RAL or another integrase strand-transfer inhibitor, were published in the JAIDS.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top